Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634824 | 0.85 | TAAR1 (0.31) | TAAR1 | |
| SCHEMBL6637168 | 0.82 | KCNN4 (0.30) | KCNN4 | |
| SCHEMBL1071791 | 0.80 | NPC1 (0.37) | TAAR1MAPTMAPK1 | |
| SCHEMBL6638415 | 0.80 | CNR2 (0.35) | — | |
| SCHEMBL1243645 | 0.79 | PDE2A (0.34) | TAAR1KCNN4MAPTKMT2AMAPK1 | |
| SCHEMBL155932 | 0.77 | TAAR1 (0.52) | TAAR1KCNN4SLC6A2TACR1MAPT | |
| SCHEMBL6667352 | 0.77 | — | — | |
| SCHEMBL6637314 | 0.77 | CYP1A2 (0.33) | — | |
| SCHEMBL8430919 | 0.76 | TAAR1 (0.35) | TAAR1 | |
| Ammonia Solution, Strong SCHEMBL28564622 | 0.74 | TAAR1 (0.50) | TAAR1KCNN4SLC6A2TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | claimed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | claimed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | claimed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | disclosed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |